Table 2.
Mouse group | Granuloma
|
Mesenteric lymph node
|
Spleen
|
||||
---|---|---|---|---|---|---|---|
CD3+CD4+ | CD3+CD8+ | CD3+CD4+ | CD3+CD8+ | CD3+CD4+ | CD3+CD8+ | ||
BL/6 | SEA/CFA-immunized | 25.64 ± 3.30 | 7.87 ± 0.21* | 32.52 ± 6.23 | 38.50 ± 8.27 | 13.25 ± 0.56 | 13.78 ± 0.30 |
SEA-immunized | 21.26 ± 1.43 | ND | 38.18 ± 1.97 | ND | ND | ND | |
CFA-immunized | 27.61 ± 6.72 | 16.28 ± 0.74 | 34.86 ± 7.80 | 33.56 ± 0.90 | 10.99 ± 1.58 | 12.60 ± 1.17 | |
control | 24.22 ± 3.40 | 19.31 ± 2.61 | 35.37 ± 7.22 | 36.66 ± 5.73 | 14.74 ± 0.67 | 17.21 ± 0.13 | |
CBA | control | 42.53 ± 5.62* | 5.80 ± 2.14* | 53.82 ± 1.00* | 28.14 ± 7.12 | 18.63 ± 3.99 | 18.53 ± 1.40 |
Pooled hepatic granuloma, MLNs and spleen cells were cultured in the presence of 20 μg/ml SEA for 36 h and stained with anti-CD3 and anti-CD4 or anti-CD3 and anti-CD8 monoclonal antibodies. The proportion of lymphocytes within each lymphocyte gate was >85% for granuloma cells, >95% for MLN cells, and >90% for spleen cells. ND, not done.
Significantly different from BL/6 control (P < 0.05).